Entering text into the input field will update the search result below

Biohaven ahead of schedule in clinical trial evaluating trigriluzole in spinocerebellar ataxia, top-line data expected in Q4

Aug. 07, 2017 7:13 AM ETBiohaven Ltd. (BHVN) StockBy: Douglas W. House, SA News Editor
  • Biohaven Pharmaceutical (NYSE:BHVN) has started dosing all of the 141 randomized subjects in its Phase 2/3 study assessing trigriluzole (formerly BHV-4157) in spinocerebellar ataxia (SCA), an inherited disorder characterized by degenerative changes in the brain related to movement control.
  • Top-line results are expected in Q4, earlier that previously expected.
  • Orphan Drug- and Fast Track-tagged trigriluzole is a novel tripeptide prodrug based on the company's glutamate modulator platform.

Recommended For You

More Trending News

About BHVN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BHVN--
Biohaven Ltd.